Thalassaemia.

Area of Science:

• Genetics
• Hematology
• Molecular Biology

Background:

• Thalassaemia comprises genetic disorders impacting globin chain synthesis globally.
• Pathogenesis involves unbalanced globin production, leading to ineffective erythropoiesis, hemolysis, and iron dysregulation.
• Clinical presentations vary widely, from asymptomatic to severe transfusion-dependent forms.

Purpose of the Study:

• To review the current understanding of thalassaemia pathogenesis.
• To discuss advancements in conservative and curative treatment strategies.
• To highlight challenges in global health resource accessibility for thalassaemia patients.

Main Methods:

• Literature review of thalassaemia pathogenesis and treatment.
• Analysis of current therapeutic approaches including transfusion, chelation, stem cell transplantation, novel agents, and gene therapy.
• Discussion of global health disparities in thalassaemia care.

Main Results:

• Conservative treatments (transfusion, chelation) have improved life expectancy, transforming thalassaemia major into a chronic condition.
• Allogeneic hematopoietic stem cell transplantation is a curative option for select patients.
• Emerging therapies, including novel agents and gene therapy, show promise in managing anemia and reducing transfusion needs.

Conclusions:

• Understanding thalassaemia pathogenesis drives therapeutic innovation.
• While treatments have advanced, significant disease burden and co-morbidities persist.
• Global health inequalities impede access to optimal care, particularly in underserved regions.